Nebicapone clinical trials
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How each study uses nebicapone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2005 | 3 |
| 2006 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Carbidopa, levodopa drug combination (2) · Resveratrol (1) · Benserazide, levodopa drug combination (1) · Levodopa (1)
Studies
Open first, then newest update. How each study uses nebicapone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedPhase 1Bial - Portela C S.A.NCT02779348Written as BIA 3-202
- Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonCompletedPhase 2Bial - Portela C S.A.NCT03103399Written as Nebicapone
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgCompletedPhase 1Bial - Portela C S.A.NCT03097211Written as Nebicapone
- Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsCompletedPhase 2Bial - Portela C S.A.NCT02834507Written as BIA 3-202
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/BenserazideCompletedPhase 1Bial - Portela C S.A.NCT02778594Written as BIA 3-202
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/CarbidopaCompletedPhase 1Bial - Portela C S.A.NCT02774564Written as BIA 3-202
- Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202CompletedPhase 1Bial - Portela C S.A.NCT02763787Written as BIA 3-202
- Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202CompletedPhase 1Bial - Portela C S.A.NCT02772627Written as Nebicapone
- Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesCompletedPhase 1Bial - Portela C S.A.NCT02772614Written as BIA 3-202 (200 mg)
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)CompletedPhase 1Bial - Portela C S.A.NCT02763839Written as BIA 3-202
- Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202CompletedPhase 1Bial - Portela C S.A.NCT02763800Written as BIA 3-202
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)CompletedPhase 1Bial - Portela C S.A.NCT02763852Written as BIA 3-202
Codes
What other systems call nebicapone · ClinicalTrials.gg INT004372
- MeSH (NLM) C433466nebicaponeOne source NLM
- UNII (FDA) NM2KXJ990TNEBICAPONEConfirmed FDA, NLM, Wikidata
- Wikidata Q21547145nebicaponeConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83923NebicaponeOne source FDA
- DrugBank DB14849One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C433466 | nebicapone | One source NLM |
| UNII (FDA) | NM2KXJ990T | NEBICAPONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21547145 | nebicapone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83923 | Nebicapone | One source FDA |
| DrugBank | DB14849 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.